Last reviewed · How we verify
semaglutide combined with metformin
semaglutide combined with metformin is a GLP-1 receptor agonist combined with biguanide Small molecule drug developed by The First Affiliated Hospital of Xiamen University. It is currently FDA-approved for Type 2 diabetes mellitus.
Semaglutide activates GLP-1 receptors to enhance insulin secretion and reduce appetite, while metformin decreases hepatic glucose production and improves insulin sensitivity.
Semaglutide activates GLP-1 receptors to enhance insulin secretion and reduce appetite, while metformin decreases hepatic glucose production and improves insulin sensitivity. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | semaglutide combined with metformin |
|---|---|
| Sponsor | The First Affiliated Hospital of Xiamen University |
| Drug class | GLP-1 receptor agonist combined with biguanide |
| Target | GLP-1R; AMPK pathway |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Semaglutide is a GLP-1 receptor agonist that stimulates insulin release in response to glucose, slows gastric emptying, and promotes satiety. Metformin is a biguanide that reduces hepatic gluconeogenesis and enhances peripheral insulin sensitivity. Together, they provide complementary glucose-lowering effects through different mechanisms.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
- Hypoglycemia
Key clinical trials
- A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes (PHASE3)
- Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. (PHASE4)
- Metabolic Surgery for Atrial Fibrillation Elimination (PHASE4)
- A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus (PHASE3)
- The Effect of Semaglutide on Bone Health (PHASE4)
- A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes (PHASE3)
- New Triple Therapy in Newly Diagnosed Type 2 Diabetes (PHASE3)
- Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- semaglutide combined with metformin CI brief — competitive landscape report
- semaglutide combined with metformin updates RSS · CI watch RSS
- The First Affiliated Hospital of Xiamen University portfolio CI
Frequently asked questions about semaglutide combined with metformin
What is semaglutide combined with metformin?
How does semaglutide combined with metformin work?
What is semaglutide combined with metformin used for?
Who makes semaglutide combined with metformin?
What drug class is semaglutide combined with metformin in?
What development phase is semaglutide combined with metformin in?
What are the side effects of semaglutide combined with metformin?
What does semaglutide combined with metformin target?
Related
- Drug class: All GLP-1 receptor agonist combined with biguanide drugs
- Target: All drugs targeting GLP-1R; AMPK pathway
- Manufacturer: The First Affiliated Hospital of Xiamen University — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Compare: semaglutide combined with metformin vs similar drugs
- Pricing: semaglutide combined with metformin cost, discount & access